Experimental combo targets Hard-to-Treat tumors
Disease control
Ongoing
This early-phase study tests a new drug called NBTXR3, which is activated by radiation, together with an immunotherapy (anti-PD-1) in people with advanced cancers that have spread. The goal is to find a safe dose and see if the combination can shrink tumors. About 145 participant…
Phase: PHASE1 • Sponsor: Nanobiotix • Aim: Disease control
Last updated May 14, 2026 20:33 UTC